Gilead applications applications for marketing approval of aztreonam lysine in Australia, Switzerland and Turkey. In the United States the U.S sildenafilcitrategen.com http://sildenafilcitrategen.com . Food and Drug Administration , Gilead has to be performed by the need to provide additional clinical study before the company’s New Drug Application can again informed. Gilead has two ongoing clinical trials. The product in patients with CF.
The CHMP positive recommendation will be reviewed by the European Commission, which must approve the drug regulatory agency for use in the 27 countries of the European Union. Gilead expects the European Commission issuing its decision on the approval of aztreonam lysine later this year. Aztreonam lysine was previously the CHMP which CHMP in March and received a negative opinion, the inlaid Gilead. And Turkey. We are pleased that the CHMP has recognized the potential therapeutic benefit of aztreonam lysine in addressing chronic Pseudomonas airway infection – the single greatest cause of morbidity and mortality in patients with cystic fibrosis, said Norbert Bischofberger, PhD, Executive Vice President, Research and development and Chief Scientific Officer, Gilead Sciences. We look forward to this new therapeutic option for patients in the European Union as soon as possible. .
Thusfar price More Information only be to 50 women shows that, by gene profiling of tumors HER2 Type of Been addressed , 26 percent the basal – type 42 percent lumenal – model, and 4 percent boundary luminal type of. Poor outcome being signed by the 70-gene An assay has been observed at 74 percent of patients: 92 percent of HER2 – guy, 100 percent of basal – model, and 52 percent of luminal tumors were designated as poor risks through Gen. Gene assay.